Neurotech Pharmaceuticals has tapped James Mazzo, former CEO of Abbott Medical Optics, as executive chairman to help advance the biotechnology company’s therapies for chronic retinal disease toward market availability, according to a company news release.
Last month, Mazzo was also named as operating partner for Versant Ventures, as well as chairman and CEO of AcuFocus, a company within the Versant portfolio.
Neurotech’s core technology platform is a patented genetically engineered implant designed to allow for continuous delivery of protein drugs directly into the vitreous, the release said. The Encapsulated Cell Technology platform could eliminate the need for monthly injections by treating a diseased retina for 2 years or more.
It may be possible to adapt the Encapsulated Cell Technology platform to generate protein drugs that can target uveitis, glaucoma and other ophthalmic indications, according to the release.